Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

13,293 total articles

Ionis Pharmaceuticals EVP Joseph Baroldi’s Spouse Executes Pre-Arranged Stock Sales and Acquisitions

Ionis Pharmaceuticals EVP Joseph Baroldi’s Spouse Executes Pre-Arranged Stock Sales and Acquisitions

Joseph Baroldi, Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals Inc. (NASDAQ: IONS), disclosed that his spouse executed a series of transactions involving the company’s common stock on June 26, 2026. The spouse sold 5,635 shares through a pre-arranged Rule 10b5-1 trading plan, generating $451,698, while simultaneously a…

...', 'subtitle': '...', 'article': '...', 'image_prompt': '...', 'news_wire_title': '...', 'sentiment': '...', 'impact': '...', 'ticker': '...', 'tickers': '...', 'ticker_sentiment': '...'}

...', 'subtitle': '...', 'article': '...', 'image_prompt': '...', 'news_wire_title': '...', 'sentiment': '...', 'impact': '...', 'ticker': '...', 'tickers': '...', 'ticker_sentiment': '...'}

Halozyme Therapeutics director Mahesh Krishnan executed a $547,800 sale of common stock in late June 2026, following the exercise of stock options. The transaction occurred as the company's shares traded near their 52-week high, reflecting a strong 48% annual return. Concurrently, Halozyme announced leadership updates and confirmed minimal long-ter…

PTC Therapeutics Executive Sells Shares Amid Strong Analyst Outlook

PTC Therapeutics Executive Sells Shares Amid Strong Analyst Outlook

Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), executed a sale of $693,151 worth of company stock on June 26, 2026. The transactions were facilitated through a Rule 10b5-1 trading plan adopted in November 2025, involving the exercise of stock options at $38.10 per share. The sale coincides with PT…